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Background: Chemotherapy response in ovarian cancer patients is frequently compromised by drug resistance, possibly due to
altered drug metabolism. Platinum drugs are metabolised by glutathione S-transferase P1 (GSTP1), which is abundantly, but
variably expressed in ovarian tumours. We have created novel ovarian tumour cell line models to investigate the extent to which
differential GSTP1 expression influences chemosensitivity.
Methods: Glutathione S-transferase P1 was stably deleted in A2780 and expression significantly reduced in cisplatin-resistant
A2780DPP cells using Mission shRNA constructs, and MTT assays used to compare chemosensitivity to chemotherapy drugs used
to treat ovarian cancer. Differentially expressed genes in GSTP1 knockdown cells were identified by Illumina HT-12 expression
arrays and qRT–PCR analysis, and altered pathways predicted by MetaCore (GeneGo) analysis. Cell cycle changes were assessed
by FACS analysis of PI-labelled cells and invasion and migration compared in quantitative Boyden chamber-based assays.
Results: Glutathione S-transferase P1 knockdown selectively influenced cisplatin and carboplatin chemosensitivity (2.3- and 4.83-
fold change in IC50, respectively). Cell cycle progression was unaffected, but cell invasion and migration was significantly reduced.
We identified several novel GSTP1 target genes and candidate platinum chemotherapy response biomarkers.
Conclusions: Glutathione S-transferase P1 has an important role in cisplatin and carboplatin metabolism in ovarian cancer cells.
Inter-tumour differences in GSTP1 expression may therefore influence response to platinum-based chemotherapy in ovarian
cancer patients.
Ovarian cancer often presents at an advanced stage where
treatment is rarely curative (Kristensen and Trope, 1997).
Chemotherapy with platinum-based drug regimens (combining
cisplatin or carboplatin with paclitaxel) can be initially effective,
but longer-term treatment is frequently compromised by the
development of drug-resistant disease (Vaughan et al, 2011).
Platinum drugs are thought to act by promoting the formation of
intra-strand DNA crosslinks, thus inhibiting DNA translation and
replication (Eastman, 1987). Although several candidate drug
resistance mechanisms, including impaired DNA repair, decreased
drug uptake, increased drug efflux and detoxification, have been
proposed (reviewed by Galluzzi et al, 2012), we are still some way
from understanding the molecular basis of drug resistance, and
from developing biomarkers to predict the onset and monitor the
development of drug-resistant disease in cancer patients.
In recent work, we used qRT–PCR analysis to quantify inter-
tumour differences in the expression of multiple candidate genes
associated with disease progression and chemotherapy response in
ovarian tumours (Smith et al, 2012). One of the most abundantly
expressed genes in ovarian tumours and tumour cell lines was
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glutathione S-transferase P1 (GSTP1, EC 2.5.1.18), a polymorphic
phase II drug-metabolising enzyme, which conjugates the anti-
oxidant tri-peptide glutathione with many toxic hydrophobic and
electrophilic xenobiotics to facilitate elimination (reviewed by
Hayes and Pulford, 1995). Increased GSTP1 expression has been
reported in pre-neoplastic lesions in chemically induced animal
cancer models (Satoh et al, 1985) and in many human tumours,
relative to surrounding normal tissues (Shea et al, 1988). Although
a useful neoplasia biomarker, it is not known whether increased
GSTP1 expression directly influences carcinogenesis, or is simply a
bystander effect, where expression of this highly inducible gene is
increased as part of the adaptive response mounted by the
neoplastic cell. In support of a direct role in carcinogenesis,
however, GSTP1 inhibits the stress-inducible c-Jun N-terminal
kinase (JNK) in vitro, and JNK activity is reduced in GSTP1 null
mice (Adler et al, 1999; Yin et al, 2000; Elsby et al, 2003).
Additional roles for GSTP1 in the regulation of genes including
TRAF2 (Wu et al, 2006), CDK5 (Sun et al, 2011) and the FAS death
receptor (Anathy et al, 2012) have also been described.
Purified GSTP1 conjugates cisplatin in vitro (Hagrman et al,
2004), and GSTP1 expression is increased in human tumour cell
lines either inherently or made resistant to chemotherapy drugs
including cisplatin and various alkylating agents (Black and Wolf,
1991; McLellan and Wolf, 1999), although a direct association
linking differential glutathione conjugation with platinum drug
resistance in human ovarian tumours has not been convincingly
demonstrated. In support of a functional association, heterologous
GSTP1 expression in Saccharomyces cerevisiae (Black et al, 1990) or
of various GSTP1 alleles in Escherichia Coli influenced sensitivity to
platinum and additional chemotherapy drugs (Ishimoto and
Ali-Osman, 2002). In contrast, similar experiments in breast cancer
MCF7 cells revealed only modest effects on platinum sensitivity
(Peklak-Scott et al, 2008), while partial GSTP1 knockdown in the
adriamycin-resistant human colorectal cancer cell line M7609
increased sensitivity not only to the selection agent, but to cisplatin,
melphalan and etoposide (Ban et al, 1996).
We therefore created novel ovarian tumour cell line models in
which GSTP1 expression is stably deleted, to investigate whether
differential GSTP1 expression directly influenced chemosensitivity
to platinum drugs, and to other drugs routinely used in the
treatment of ovarian cancer patients. We have used whole-genome
transcriptional profiling analysis and various quantitative pheno-
typic assays to identify gene expression and associated phenotypic
differences in parental and GSTP1 knockdown cell lines.
MATERIALS AND METHODS
Ovarian tumour cell lines. A2780 and cisplatin-resistant deriva-
tive A2780DPP cells were obtained from ATCC (LGC Standards,
Teddington, UK), via Cancer Research UK Cell Services. A2780
cells were maintained in RPMI-1640 media supplemented with
10% FBS, and A2780DPP cells (derived in vitro following long-
term cisplatin selection; Behrens et al, 1987) in RPMI-1640 media
supplemented with 15% FBS and 1mM cisplatin. Both cell lines
were maintained in 37 1C incubators, supplemented with 5% CO2.
Creation and characterisation of stable GSTP1 knockdown cell
lines. Glutathione S-transferase P1 expression was stably knocked-
down in A2780 and expression significantly reduced in A2780DPP
cells by RNA interference using Mission shRNA plasmids (Sigma-
Aldrich, Gillingham, UK). Five unique GSTP1-specific shRNA
plasmids (clones TRCN0000083773, TRCN0000083774, TRCN000
0083775, TRCN0000083776 and TRCN0000083777) and a negative
control plasmid (empty vector control, SHC001) were purchased
as glycerol stocks and plasmid DNA extracted using plasmid
DNA maxi prep kits (Qiagen, Manchester, UK) according to the
manufacturer’s instructions. A2780 and A2780DPP cells (2.5 105
cells per well in six-well plates) were transfected with each plasmid
using lipofectamine (Life Technologies, Paisley, UK), and shRNA-
containing cells selected with puromycin. Individual cell colonies
were picked using cloning cylinders, harvested for mRNA analysis
(A2780DPP cells) or expanded to 75 cm2 tissue culture flasks and
harvested for mRNA and protein analysis (A2780 cells). GSTP1
knockdown in A2780 cells was confirmed by qRT–PCR analysis
and western blotting, and by qRT–PCR analysis in A2780DPP
cells. Cell growth rates were compared by plating 1 105 cells from
each cell line in individual wells of six-well dishes (day 0). Cells
were harvested daily by trypsinisation (days 2–10) and counted
using a haemocytometer.
RNA extraction and qRT–PCR analysis. Cells were grown to
80% confluency in 75 cm2 flasks, harvested by trypsinisation,
counted using a haemocytometer, and 1 107 cells used for RNA
extraction using a Qiagen RNeasy mini kit (Qiagen), following the
manufacturer’s protocol for mammalian cells, with additional on
column DNAse digestion (RNAse free DNAse kit, Qiagen). RNA
yield and integrity were initially assessed from absorbance readings
at 260 and 280 nm using a Nanodrop 1000 spectrophotometer
(Thermo Fisher Scientific, Loughborough, UK), and confirmed
using an Agilent Bioanalyzer 2100 and RNA 6000 Nano LabChip
Kit (Agilent Technologies, Wokingham, UK) according to the
manufacturer’s guidelines.
RNA was reverse transcribed into cDNA (50 ng RNA per 20 ml
RT reaction) using High Capacity RNA to cDNA kits (Life
Technologies) according to the manufacturer’s instructions, and
the expression of GSTP1 (Taqman probe ID Hs00168310_m1) and
the loading control 18S ribosomal RNA (Hs03003631_g1) assessed
by qRT–PCR analysis, as previously described (Smith et al, 2012),
where 20 ml individual reaction mixes (per well) contained 10 ml
Taqman Universal PCR Master Mix (Life Technologies), 1ml gene-
specific Taqman probe, 1 ml cDNA and 8ml sterile water. Each
reaction was performed in triplicate and run on the Standard Real-
Time PCR program on a 7900 Taqman real-time PCR system
(Applied Biosystems, Warrington, UK) using pre-defined thermal
cycling conditions (50 1C for 2min, 94.5 1C for 10min, 40 cycles of
(97 1C for 30 s and 59 1C for 1min)). Similarly, the expres-
sion of ALX1 (Hs00232518_m1), CDH2 (Hs00983056_m1),
FOXC1 (Hs00559473_s1), LAYN (Hs00379511_m1), TM4SF
(Hs00371661_m1) and VCAN (Hs00171642_m1) was additionally
investigated by qRT–PCR analysis in A2780 and A2780/GSTP1
cells. Analysis was performed using SDS 2.3 software (Applied
Biosystems); optimal experimental baselines and thresholds were
chosen for each gene, and gene expression quantitated by cycle
threshold (Ct) values. Relative expression values were determined
by comparing the expression of each target gene with the invariant
‘loading control’ 18S ribosomal RNA, as previously described
(Smith et al, 2012). All samples were analysed in triplicate and gene
expression calculated relative to 18S ribosomal RNA±compound
error ((s.d. target gene)2þ (s.d. 18S ribosomal RNA)2)½, where
s.d.¼ standard deviation of the mean of triplicate replicates.
Whole-genome microarray mRNA analysis in A2780 and
A2780/GSTP1 cells. RNA was prepared from A2780 and
A2780/GSTP1 cells and integrity assessed as described above. Each
RNA sample was converted to biotinylated amplified cRNA using
an Illumina TotalPrep RNA Amplification kit (Life Technologies)
according to the manufacturer’s guidelines, and cRNA quality and
concentration confirmed on the Agilent Bioanalyzer 2100, as
described above. cRNA samples were hybridised in triplicate on
Illumina Human HT-12 BeadChip Arrays (Illumina, Little
Chesterford, UK) using standard protocols optimised by the
Genetics Core, Wellcome Trust Clinical Research Facility,
University of Edinburgh.
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Bioinformatics analysis. Gene expression data were analysed
using Bioconductor 2.7 (http://bioconductor.org), running on
R 2.12.1. Normalised probeset expression measures were calculated
using log2 transformation and quantile normalisation using the
‘Lumi’ package. To identify significant differences in gene
expression in A2780 and A2780/GSTP1 cells, moderated Student’s
t-tests were performed using empirical Bayes statistics in the
‘Limma’ package, and resulting P-values adjusted for multiple
testing using the false discovery rate (FDR) Benjamini and
Hochberg method (Smyth, 2004); probe sets with adjusted P-value
FDR qo0.05 were called differentially expressed. Differentially
expressed probes were also subjected to Metacore Pathway analysis
(Thomson Reuters, London, UK) to identify enrichment of
pathways and processes, using hyper-geometric distributions to
determine the most enriched gene sets (FDR qo0.05).
Protein expression and western blotting. Cells for protein
extraction were plated in six-well dishes, cultured until confluent,
growth media removed and washed with ice-cold PBS before lysis
in 0.5ml RIPA buffer (50mM Tris-HCl, 150mM NaCl, 5mM
EDTA, 0.1% SDS, 0.5% sodium deoxycholate, 1% Nonidet P-40)
supplemented with 2% protease inhibitor cocktail (Sigma-Aldrich).
Lysed cells were centrifuged (13 000 r.p.m; 10min) to pellet cell
debris, and protein concentrations of the resulting cell
supernatants determined by Bradford Assay (Bio-Rad, Hemel
Hempstead, UK), relative to a standard curve prepared from serial
dilutions of bovine serum albumin (0–1mgml–1), with absorbance
readings at 595 nm.
Glutathione S-transferase P1 expression was analysed in protein
extracts from each cell line by western blotting, following SDS-
PAGE. Each protein sample (40 mg) was diluted in equal volumes
of 5 sample buffer (10% SDS, 250mM Tris-HCl (pH 6.8),
1mgml–1 bromophenol blue, 0.5 M DTT, 50% glycerol), denatured
and separated by SDS-PAGE using 12% Mini-PROTEAN 3
polyacrylamide gels (Bio-Rad) in Tris-glycine buffer (25mM Tris
pH 8.3, 250mM glycine, 0.1% SDS). Following electrophoresis,
proteins were transferred to nitrocellulose membranes in Tris-
glycine-methanol buffer (48mM Tris pH 8.3, 39mM glycine,
0.037% SDS, 10% methanol) and nonspecific antibody binding
blocked by incubation for 2 h in TBST (25mM Tris-HCl pH 7.6,
150mM NaCl, 0.05% Tween-20) containing 5% milk powder.
Membranes were then incubated overnight with a rabbit polyclonal
GSTP1 primary antibody ((Henderson et al, 1998), diluted 1 : 1000)
or a mouse monoclonal b-actin antibody (sc-47778, Santa Cruz
Biotechnology Inc., Heidelberg, Germany, diluted 1 : 1000), washed
in PBST (PBS supplemented with 0.05% Tween-20) and incubated
for 1 h with a swine anti-rabbit polyclonal secondary antibody
(Dako PO399, diluted 1 : 1000, GSTP1, Dako, Ely, UK) or goat
anti-mouse polyclonal secondary antibody (Dako PO447, diluted
1 : 1000, b-actin). Immunoblots were developed using an ECL-
chemiluminescence kit (Merck Millipore, Watford, UK) according
to the manufacturer’s instructions.
Analysis of cellular glutathione levels. Total cellular glutathione
(GSSGþGSH) levels were compared in A2780 and A2780/GSTP1
cells using a Glutathione Assay kit (Sigma-Aldrich) according to
the manufacturer’s guidelines. Cells were harvested, washed in
PBS, counted using a haemocytometer and re-suspended to a final
concentration of 1 108 cellsml–1 in PBS. Cells were then pelleted,
de-proteinised with 5% 5-sulfosalicyclic acid and glutathione levels
assessed using a kinetic assay in which catalytically active
glutathione reduces 5,5-dithiobis(2-nitrobenzoic acid) (DTNB) to
5-dithiobis(2-nitrobenzoic acid) (TNB). TNB production was
measured spectrophotometrically at 412 nm, with kinetic reads at
1-min intervals for 5min, and glutathione levels extrapolated from
a standard curve of serial dilutions of reduced glutathione (positive
values for both GSH and GSSG are obtained in the reaction).
Ovarian cell line chemosensitivity assays. MTT assays
(Mosmann, 1983) were used to compare chemosensitivity of
A2780 and A2780/GSTP1 cells to the GSTP1 model substrate
ethacrynic acid and chemotherapy drugs cisplatin, carboplatin,
paclitaxel, doxorubicin, topotecan and gemcitabine. Each cell line
was plated in a 96-well plate (5000 cells per well) and treated in
triplicate with serial dilutions of each drug. Ethacrynic acid was
used at concentrations from 2.5 to 80 mM, and chemotherapy drugs
at concentrations selected to mimic typical peak plasma levels in
ovarian cancer patients (range 0–200% (peak plasma); cisplatin
0–25 mM, carboplatin 0–85 mM, paclitaxel 0–32 mM, doxorubicin
0–6mM, gemcitabine 0–190mM and topotecan 0–56mM; Konecny
et al, 2000). Cells were drug treated for 72 h, media removed and
100ml of a 0.5mgml–1 MTT solution (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide in phenol red-free DMEM) added
and cells incubated at 37 1C for 3 h. The resulting formazan crystals
were solubilised in DMSO, quantitated spectrophotometrically at
570 nm and the percentage of live cells remaining following each
drug treatment calculated (assigning a value of 100% to vehicle-
treated cells). IC50 values were calculated from log dose-response
curves using Prism 6 software (GraphPad Software Inc., La Jolla,
CA, USA).
Cell invasion and migration assays. Cell invasion and migration
was assessed using 24-well InnoCyte Cell Invasion and Migration
Assays (Merck Millipore) according to the manufacturer’s guide-
lines. Cell invasion was assessed by plating cells in serum-free
medium in invasion chambers (8mm membranes) coated with
basement membrane matrix, which prevents non-invasive cells
from passing through the membrane pores. Similarly, cell
migration was compared in A2780 and A2780/GSTP1 cells by
plating each cell line in serum-free medium in migration chambers.
In both assays, serum-containing medium was added to each well
to induce cell migration, assessed by staining cells attached to the
lower side of the membrane with the fluorescent cell permeable dye
Calcein-AM, and measuring fluorescence at 485 nm (excitation)
and 520 nm (emission). Negative control A2780 cells were
additionally treated with the anti-migratory drug Latrunculin A.
FACS analysis. Cell cycle parameters were compared in A2780
and A2780/GSTP1 cells by flow cytometry following propidium
iodide labelling of cell line DNA. Cells were untreated, or treated
with 12.66 mM cisplatin (to represent typical 100% patient peak
plasma levels) for 1, 4 or 24 h then fixed in ice-cold 70% ethanol
overnight at  20 1C, re-suspended in PBS and stained by
incubation with propidium iodide (40 mgml–1, Sigma-Aldrich)
and RNAse A (100 mgml–1, Sigma-Aldrich) for 30min at 37 1C in
the dark. Cell cycle parameters (10 000 cells per sample) were
analysed using a FACScan flow cytometer (Becton Dickinson,
Oxford, UK) and Cellquest Pro software to determine cell cycle
phases and cells in sub-Go/G1.
Statistical analysis. All statistical tests were performed using the
SPSS statistics package version 20.0 (IBM, New York, NY, USA).
Independent sample t-tests were used to assess differences in gene
expression identified by qRT–PCR analysis and invasion and
migration changes in A2780 and A2780/GSTP1 cells.
RESULTS
We previously showed that GSTP1 is abundantly expressed in
human ovarian tumours, and highlighted marked inter-tumour
differences in GSTP1 expression (Smith et al, 2012). To investigate
whether individuality in GSTP1 expression influences chemother-
apy response, we used shRNA-mediated gene silencing to stably
knockdown GSTP1 in the ovarian tumour cell line A2780, created
from a chemotherapy-naive ovarian cancer patient (Behrens et al,
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1987). A2780 cells were transfected with each of five GSTP1-
specific Mission shRNA pLKO.1-puro plasmids (773, 774, 775, 776
and 777) and a negative control plasmid as described in Materials
and Methods section. Following lipofectamine selection, multiple
antibiotic-resistant colonies were screened for GSTP1 knockdown
by qRT–PCR analysis, and gene knockdown confirmed in cells
transfected with plasmids 773, 775 and 776 (Figure 1A), with
maximum reduction in shRNA construct 775 and 776-transfected
cells. GSTP1 protein expression was evaluated by western blotting,
with complete loss of GSTP1 expression confirmed in shRNA
construct 775-transfected cells and 495% reduction in protein
expression in construct 776-transfected cells (Figure 1B). GSTP1-
775 knockdown cells (A2780/GSTP1) were therefore selected for
use in additional experiments, following additional confirmation of
increased total cellular glutathione levels (A2780 83.16±1.67 mM
and A2780/GSTP1 116.85±4.67 mM), consistent with reduced
GSTP1 catalytic activity.
MTT assays were then used to compare chemosensitivity of
A2780 and A2780/GSTP1 cells to the diuretic and well-
characterised GSTP1 substrate ethacrynic acid. GSTP1 conjugates
and detoxifies ethacrynic acid (Ahokas et al, 1984), which was
significantly more toxic to GSTP1 null cells (1.3-fold increase in
IC50, P¼ 0.004, Figure 2A). Sensitivity to platinum-based che-
motherapy drugs was then compared in A2780 and A2780/GSTP1
cells and significant differences in chemosensitivity observed
following treatment with cisplatin (2.28-fold decrease in IC50,
P¼ 0.03, Figure 2B) and carboplatin (4.83-fold decrease in IC50,
P¼ 0.007, Figure 2C), and a less pronounced decrease in sensitivity
to paclitaxel (1.58-fold increase in IC50, P¼ 0.02, Figure 2D).
Chemosensitivity to additional drugs used to treat ovarian cancer
was also compared but no significant differences in IC50 values
identified (doxorubicin 0.13 vs 0.11 mM, gemcitabine 3.32 vs 3.34 mM
and topotecan 1.00 vs 1.12 mM in A2780 and A2780/GSTP1 cells,
respectively (all P-values 40.05)). To confirm our findings, MTT
assays were repeated in GSTP1-776 cells and very similar changes
in cisplatin, carboplatin and paclitaxel chemosensitivity identified
(data not shown).
As GSTP1 knockdown significantly increased cisplatin and
carboplatin chemosensitivity in A2780 cells, we further investigated
whether GSTP1 knockdown in the related platinum-resistant
A2780DPP cell line (Behrens et al, 1987) could re-sensitise these
drug-resistant cells to platinum-based chemotherapy. A2780DPP
cells were therefore transfected with shRNA constructs 775 and 776,
optimised for GSTP1 knockdown in the experiments described
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Figure 1. Generation of stable GSTP1 knockdown cell lines. A2780
ovarian tumour cells were transfected with various GSTP1 Mission
shRNA constructs (clones 773, 774, 775, 776 and 777) and an empty
vector negative control plasmid as described in Materials and Methods
section. Following puromycin selection, GSTP1 expression was
compared in A2780 cells and in each novel daughter cell line (A) by
qRT–PCR analysis, relative to 18S ribosomal RNA (significant
differences in gene expression (Po0.05) are highlighted) and (B) by
western blot analysis of clones 775 and 776 to confirm loss of GSTP1
protein expression.
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Figure 2. Chemosensitivity changes induced by stable GSTP1 knockdown in A2780 cells. MTT cytotoxicity assays were used to compare
chemosensitivity to (A) ethacrynic acid, (B) cisplatin, (C) carboplatin and (D) paclitaxel in A2780 and A2780/GSTP1 cells as described in Materials
and Methods section. Cisplatin, carboplatin and paclitaxel were used at doses representative of typical peak plasma levels in ovarian cancer
patients. Each assay was performed in triplicate—mean data from three independent experimental replicates is illustrated.
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above. In contrast to drug-sensitive A2780 cells, however, although
puromycin-resistant colonies were initially formed in A2780DPP
cells in multiple replicate experiments, the colonies formed were
relatively small (10–20 cells per colony) and were viable for only 48 h
(Figure 3A). As our control transfections resulted in viable colony
formation in both A2780 and A2780DPP cells, we hypothesised that
GSTP1 knockdown may be lethal in A2780DPP cells, which are
grown in medium containing 1mM cisplatin to maintain the drug-
resistant phenotype. To confirm GSTP1 knockdown in A2780DPP
cells, we isolated individual puromycin-resistant colonies 24 h after
colony formation using cloning cylinders, and extracted sufficient
RNA to confirm GSTP1 knockdown by qRT–PCR analysis
(Figure 3B). Unfortunately, we were unable to harvest sufficient
A2780DPP/GSTP1 knockdown cells to perform western blotting,
cytotoxicity assays or more detailed phenotypic characterisation, but
our confirmation of GSTP1 knockdown, together with selective
platinum toxicity in puromycin-resistant clones is consistent with an
essential role for GSTP1 in glutathione conjugation and cisplatin
detoxification. We further attempted to confirm this hypothesis by
knocking down GSTP1 in A2780DPP cells grown in the absence of
cisplatin selection, but found that control untransfected A2780DPP
cells did not retain a stable drug-resistant phenotype over the 6-week
experimental period in the absence of cisplatin selection (data not
shown).
To investigate the cellular phenotypes resulting from GSTP1
knockdown in A2780 cells, Illumina HT-12 Expression BeadChip
Arrays were used to compare gene expression in A2780 and
A2780/GSTP1 cells. Each HT-12 array contains 447 000 unique
probe sets, corresponding to 428 000 coding transcripts; 2671
probes were significantly more highly expressed, and 2717 probes
less highly expressed in A2780/GSTP1 cells. Of these, X2-fold
differences in gene expression were identified for 336 gene
transcripts—the most significantly differentially expressed genes
are summarised in Supplementary Table 1 (Supplementary
Information), and changes in gene expression predicted by
BeadChip Array analysis confirmed by qRT–PCR analysis for
selected up- and downregulated genes (Figure 4). It was of
particular interest to note that no compensatory changes in
additional GST isoforms were identified in A2780/GSTP1 cells.
Pathway and process enrichment analysis was then used to
identify common differentially regulated pathways or processes in
A2780 and A2780/GSTP1 cells (Supplementary Table 2). Consistent
with these predictions, the most significant differences in gene
expression were seen for genes (e.g., N-cadherin (CDH2), versican
(VCAN), L6 cell surface antigen (TM4SF1) and layilin (LAYN))
associated with cell invasion, migration, metastasis and the
epithelial–mesenchymal transition. Consistent with known functions
of the GSTs, several differentially regulated pathways and processes
were associated with lipid metabolism and with the oxidative stress
response, while additional interesting associations suggested altered
cell cycle regulation and differences in apoptosis, cell invasion and
migration. We therefore used quantitative cell growth, invasion and
migration assays and FACS analysis to compare A2780 and A2780/
GSTP1 cell phenotypes. We did not observe significant differences in
cell growth rates, where A2780 and A2780/GSTP1 cells had
doubling times of 0.91 and 1.03 days, respectively (P¼ 0.462), or
in cell cycle parameters, assessed by FACS analysis of propidium
iodide-labelled untreated cells and stressed cells acutely treated with
cisplatin (Figure 5A). In contrast, consistent with the gene
expression and pathway/process differences described above, we
found that both cell invasion (Figure 5B) and migration (Figure 5C)
was significantly reduced in A2780/GSTP1 cells.
DISCUSSION
Conjugation of glutathione with platinum-based chemotherapy drugs
is an important detoxification mechanism, which promotes drug
clearance, limits the formation of DNA crosslinks and reduces toxicity
(Peklak-Scott et al, 2008). It is therefore logical that the expression of
glutathione-conjugating enzymes including GSTP1 is increased as an
adaptive response in drug-resistant tumour cells (Black and Wolf,
1991; McLellan andWolf, 1999) and that reduced GSTP1 activity may
influence chemosensitivity. Several studies, however, have described
increased GSTP1 expression in drug-resistant cell lines following
exposure to drugs which are not detoxified by glutathione conjugation
(Wang et al, 1989), or which are not GSTP1 substrates (Tew, 1994)—
a direct role for GSTP1 in platinum chemosensitivity therefore
remains to be unequivocally established.
We have shown for the first time that stable deletion of GSTP1
in A2780 ovarian tumour cells significantly and selectively
increases sensitivity to cisplatin and carboplatin, drugs routinely
used to treat ovarian cancer, a notoriously drug-resistant and
clinically intractable disease. Importantly, loss of GSTP1 expression
in the cisplatin-resistant A2780 subline A2780DPP was toxic to the
cells in the presence of cisplatin, consistent with an important
catalytic role for GSTP1 in glutathione conjugation in the
detoxification pathway of platinum drugs. Consistent with this
hypothesis, we found significant differences in intracellular
glutathione levels and in sensitivity to the GST substrate ethacrynic
acid in GSTP1 null cells. Although the role of GSTP1 in ovarian
A2
78
0
A2
78
0D
PP
GSTP1 (clone 775)
P<0.001
P<0.001
Negative control
0.001
0.0009
0.0008
0.0007
0.0006
0.0005
0.0004
0.0003
0.0002
0.0001
0
A2780DPP A2780DPP
negative
A2780DPP/
GSTP1 clone
775
A2780DPP/
GSTP1 clone
776
GSTP1 (clone 776)
R
el
at
iv
e 
ex
pr
es
sio
n
Figure 3. GSTP1 knockdown is toxic to cisplatin-resistant A2780DPP
cells. A2780 and cisplatin-resistant A2780DPP cells were transfected
with GSTP1 Mission shRNA plasmids 775 and 776 or an empty vector
negative control plasmid, as described in Materials and Methods
section, and GSTP1 knockdown cells identified by puromycin selection.
(A) Viable puromycin-resistant colonies were obtained from all
transfections in A2780 cells, but only from A2780DPP cells transfected
with an empty vector negative control plasmid. (B) qRT–PCR analysis
was used to confirm GSTP1 knockdown in A2780DPP cells (illustrated
relative to the expression of 18S ribosomal RNA) following transfection
of GSTP1 shRNA clones. Cells from small colonies with limited viability
were collected using cloning cylinders, and RNA extracted as
described in Materials and Methods section.
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tumour chemosensitivity has not been studied, transient siRNA-
mediated GSTP1 knockdown in a diverse panel of leukaemia and
lymphoma cell lines has recently also been reported to influence
cisplatin sensitivity (Chen et al, 2013).
Glutathione S-transferase P1 has also been proposed to have a
non-catalytic role in promoting cell proliferation by binding to and
inhibiting JNK (Adler et al, 1999)—JNK activity is increased when
GSTP1 activity is reduced, either by small molecule GSTP1
inhibitors or in GSTP1 null mice (Henderson et al, 1998). It is
logical to propose, therefore, that stable GSTP1 deletion in A2780
ovarian tumour cells may result in JNK activation. Consistent with
this hypothesis, interrogation of our gene expression microarray
data sets revealed increased expression of several JNK regulatory
genes including the toxicity and JNK inducer TAJ (TNFRSF19,
8.33-fold, adjusted P-value 1.25 10 18, Supplementary Table 1),
and JNK target genes including the p53-inducible proteins TP53I3
(PIG3, 5.02-fold, adjusted P-value 1.73 10 16) and CDKN1A
(p21, 4.87-fold, adjusted P-value 9.62 10 15) in GSTP1 knock-
down cells. Although many of the genes up- and downregulated by
GSTP1 deletion are associated with the RAS/MAPK pathway
(Supplementary Table 1), we did not detect a significant difference
in RAS/MAPK pathway activation, using a quantitative RAF-1-
binding/Ras GTPase ELISA to assess pathway activation in GSTP1
knockdown cells (data not shown). In contrast, several differen-
tially expressed genes (e.g., CDH2) and associated pathways and
processes suggested that GSTP1 knockdown may significantly
inhibit cell invasion and migration—these predictions were
confirmed experimentally, and are consistent with the hypothesis
that increased GSTP1 expression promotes neoplastic transforma-
tion and the development of drug resistance. We were therefore
surprised to find that GSTP1 knockdown did not significantly
influence cell growth rate or alter cell cycle progression in A2780
cells, although similar findings have been reported in a series of
ovarian cancer cell lines made resistant to cisplatin, carboplatin
and paclitaxel (Li et al, 2004), suggesting limitations of the use of
immortalised cancer cell line models. Similarly, and consistent with
a previous report of comparable GSTP1 expression in A2780 cells
and the cisplatin-resistant derivatives C70 and C200 (Townsend
et al, 2002), we did not detect a significant increase in GSTP1
expression in platinum-resistant A2780DPP cells. In contrast,
increased GSTP1 expression has been described in many drug-
resistant cell lines (Kuroda et al, 1991; Kotoh et al, 1997; Tozawa
et al, 2008; Yang et al, 2009), including ovarian tumour lines
resistant to platinum drugs (Lewis et al, 1988; Parekh and
Simpkins, 1996; Yanagie et al, 2009). Recent data from our own
laboratory, where we see increased GSTP1 expression in a novel
drug-resistant A2780 subline immediately following de novo
platinum selection, further support the hypothesis that increased
GSTP1 expression may not be maintained in long-term culture of
immortalised tumour cells. In light of these concerns, we are
currently extending our analysis to additional immortalised cell
lines, with different histologies and genetic backgrounds and to
primary cell lines derived from ascites from drug-sensitive and
drug-resistant ovarian cancer patients.
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Figure 4. qRT–PCR analysis confirms gene expression changes predicted by Illumina Beadchip microarray analysis of A2780 and A2780/GSTP1
cells. qRT–PCR was performed, as described in Materials and Methods section, to confirm differential expression of selected genes predicted by
comparative Illumina HT-12 Beadchip Array analysis to be differentially expressed in A2780 and A2780/GSTP1 cells—(A) VCAN, (B) FOXC1,
(C) ALX1, (D) TM4SF, (E) CDH2 and (F) LAYN. All samples were analysed in triplicate; gene expression is illustrated relative to the expression of 18S
ribosomal RNA.
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Glutathione S-transferase P1 expression in cancer patients may
also be influenced by the presence of allelic variants—GSTP1
Ile105Val (rs1695) and GSTP1 Ala114Val (rs1138272), with homo-
zygote rare allele frequencies of approximately 12% and 2% in the
Caucasian population, respectively (Zimniak et al, 1994;
Ali-Osman et al, 1997; Harries et al, 1997; Sachse et al, 2002).
Unlike GSTM1 and GSTT1, however, where common polymorph-
isms result in complete gene deletions (Board, 1981), variant GSTP1
alleles differ from the consensus reference sequence by single amino-
acid substitutions, resulting in less pronounced, less frequent and
less well-characterised phenotypes (Peklak-Scott et al, 2008).
In contrast, however, our recent gene expression profiling
experiments in human ovarian tumours describe marked (470-fold)
inter-tumour differences in GSTP1 expression, suggesting that
individuality in glutathione-conjugating activity, although not
genetically determined, could significantly influence response to
platinum-based chemotherapy in ovarian cancer patients.
Studying the influence of inter-individual differences in GSTP1
expression on disease progression or chemotherapy response in
ovarian cancer patients is challenging—the disease is frequently
diagnosed at an advanced stage, limiting the availability of
matched normal and tumour samples, and serial matched drug-
sensitive and drug-resistant tumour biopsies are rarely available.
Increased GSTP1 expression in ovarian tumours (n¼ 41), relative
to unmatched healthy ovarian samples (n¼ 12) and benign
tumours (n¼ 25) has been described in a small Chinese study
(Cheng et al, 2000) and, consistent with our findings, GSTP1
expression in ovarian cyst fluid has been correlated with higher
relapse rates following platinum-based chemotherapy (Boss et al,
2001). In similar studies, GSTP1 expression in ovarian cyst fluid
correlated both with serum CA125 levels and reduced patient
survival (Kolwijck et al, 2009), while in a small series (n¼ 30)
of matched first and second-look laparotomies, increased
GSTP1 expression was associated with disease progression,
assessed by both more frequent relapses and reduced survival
(Surowiak et al, 2005).
Confirmation of a direct role for GSTP1 in chemotherapy
response is important, not only in the prediction of response to
platinum-based chemotherapy, but as a candidate response
biomarker for new generation chemotherapy drugs, designed to
exploit increased GSTP1 expression in tumours relative to
surrounding normal tissues. For example, TLK-286 (Telcyta,
canfosfamide) was identified as the lead candidate in a rationally
designed series of selectively toxic glutathione analogues (Lyttle
et al, 1994), which continues to be evaluated both as a single agent
and in combination chemotherapy in phase II and III clinical trials
in ovarian cancer and other solid tumours. TLK-286 is metabo-
lically activated by GSTP1 and cytotoxicity has been correlated
with GSTP1 expression (Rosario et al, 2000; Dourado et al, 2013).
Increased GSTP1 expression in tumours and in drug-resistant cells
is also the target of a new class of GST suicide inhibitors, including
7-nitro-2,1,3-benzoxadiazole (NBDHEX) (Ricci et al, 2005), which
acts to induce apoptosis by promoting dissociation of the GSTP1/
JNK1 complex in leukaemia cell lines (Turella et al, 2005). Similar
effects were recently observed in mesothelioma cell lines, where
NBDHEX synergised with cisplatin (De Luca et al, 2013).
We have described marked inter-tumour differences in GSTP1
expression but, unlike fibroblast growth factor (FGF) family genes,
pre-treatment tumour GSTP1 expression was not influenced by
tumour histology or associated with altered survival (Smith et al,
2012). Our study did not have sufficient power to perform a
meaningful assessment of the potential role of GSTP1 in chemother-
apy response, although we believe that lack of routine access to
comparable clinical biopsy or tumour samples from ovarian cancer
patients pre- and post-treatment may significantly limit tumour
biomarker utility. It is interesting to note, however, that post-
chemotherapy GSTP1 expression was associated with progression-free
survival in a small study (n¼ 41 patients) where pre- and post-
chemotherapy biopsies were available (Saip et al, 2005). We are
therefore currently recruiting ovarian cancer patients to clinical
studies in which we are collecting serial serum and ascites samples
from matched drug-sensitive and drug-resistant patients for
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Figure 5. Phenotypic comparison of A2780 and A2780/GSTP1 knockdown cells. (A) FACS analysis of PI-labelled cells was used, as described in
Materials and Methods section, to compare cell cycle progression of A2780 and A2780/GSTP1 cells, before and following cisplatin challenge.
Each sample was analysed in triplicate—the relative proportions of cells in each phase of the cell cycle at each time point is illustrated. Boyden
chamber-based (B) invasion (using cell culture media supplemented with 10% FBS as chemoattractant) and (C) migration (ECMatrix) assays were
then used to compare predicted phenotypes in negative (Latrunculin A-treated) controls, A2780 and A2780/GSTP1 cells as described in Materials
and Methods section.
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quantitative biomarker profiling. GSTP1 expression has previously
been investigated by immunostaining in ovarian ascites samples, and
shown to correlate with both primary tumour expression and cisplatin
chemosensitivity (Kase et al, 1998). Our microarray data sets provide
numerous examples of GSTP1-dependent gene expression changes,
and may therefore allow us to identify additional biomarkers, which
correlate with GSTP1 activity. Additional candidate GSTP1 biomar-
kers have recently identified in studies describing an inverse
association between GSTP1 expression, chemosensitivity and expres-
sion of the regulatory microRNA miR-513a-3p in cisplatin-resistant
A549 lung cancer cells (Zhang et al, 2012). Similarly, interleukin-6
(IL-6) production has been shown to be elevated in both serum and
ascites samples from ovarian cancer patients and to be inversely
associated with platinum chemosensitivity and survival (Scambia et al,
1995). Of obvious relevance to our findings, GSTP1 has recently been
shown to be an IL-6 target gene (Wang et al, 2010), while inhibition of
GSTP1 activity by an IL-6 or IL-6 receptor mAb correlates with
increased platinum (and paclitaxel) sensitivity in renal cancer cells
(Mizutani et al, 1995). It will therefore be of particular interest to
compare GSTP1 and IL-6 levels in serum and ascites samples from
drug-sensitive and drug-resistant ovarian cancer patients.
In summary, and consistent with the findings of a recent similar
study in mesothelioma (Chen et al, 2014), we have shown that
GSTP1 selectively influences sensitivity to cisplatin and carboplatin
in ovarian tumour cells. Additional studies to evaluate the role of
GSTP1 and co-regulated genes as clinical response biomarkers of
disease progression and platinum chemosensitivity in ovarian
cancer patients are underway in our laboratory.
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